Wegovy maker Novo Nordisk to cut costs as weight-loss competition heats up

Wegovy maker Novo Nordisk warns of layoffs as competition grows

Sales slump especially in the US market as Wegovy’s grip on the obesity drug market loosens.

Novo Nordisk CEO Warns of Layoffs as Wegovy Challenge Heats Up

Wegovy maker Novo Nordisk to cut costs as weight-loss competition heats up

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity drug, with lower growth expected for its treatments in the second half of the year.

Novo Nordisk doubles down on Trump-friendly sale strategy

Chief financial officer Karsten Munk Knudsen said that the pharma giant's cash channel was key to regaining market share and meeting U.S. policy needs.

Novo’s Growth Sputters as US Competition Dents Obesity Sales

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in the crucial US market for obesity medicines, underscoring the slowdown that prompted last week’s profit warning.